Skip to main content
Contact
Site Search
Home
About
Who We Are
Leadership
Our Legacy
Science
Overview
Publications
Pipeline
Overview
Clinical Trials
Patients
Therapeutic Focus
Patient Resources
Access Policy
News/Events
Overview
Press Releases
Events & Presentations
Email and News Alerts
Careers
Overview
Our Values
Inside Momenta
Benefits
Search Openings
Home
About
Who We Are
Leadership
Our Legacy
Science
Overview
Publications
Pipeline
Overview
Clinical Trials
Patients
Therapeutic Focus
Patient Resources
Access Policy
News/Events
Overview
Press Releases
Events & Presentations
Email and News Alerts
Careers
Overview
Our Values
Inside Momenta
Benefits
Search Openings
Publications
Home
>
Science
>
Publications
Novel Therapies
Nipocalimab (M281), Anti-FcRn Antibody
Clinical Pharmacology & Therapeutics publication containing the full data from the Phase 1 Study Data for Anti-FcRn Antibody, nipocalimab (M281), entitled:
Nipocalimab (M281), an Anti-FcRn Antibody: Pharmacodynamics, Pharmacokinetics and Safety across the Full Range of IgG Reduction in a First-In-Human Study
A Therapeutic FcRn Blocking Antibody for Rapid Clearance of IgG and IgG Autoantibodies in Immune Cytopenias and other Autoimmune Diseases
View Poster
Targeting the Neonatal Fc Receptor (FcRn) to Mediate Autoantibody Clearance in IgG-driven Autoimmune Disease
View Poster
M254, Hyper-sialylated lgG (hslgG)
Hyper-sialylated IgG M254, an Innovative Therapeutic Candidate, Evaluated in Healthy Volunteers and Patients With Immune Thrombocytopenia Purpura: Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics --- Santiago Arroyo, MD, PhD; Renger G. Tiessen, MD, PhD; William S. Denney, PhD; Jim Jin, MS; Mattheus Paulus (Thijs) van Iersel, MD; Heidi Zeitz, MEd, CCRA; Anthony M. Manning, PhD; Martin R. Schipperus, MD, PhD; James B. Bussel, MD;
American Society of Hematology Annual Meeting, December 7, 2019.
View Poster
Anti-inflammatory Activity of IgG-Fc; C. Beneduce, E. Kurtagic, C.J. Bosques; Current Topics in Microbiology and Immunology (2019) 423: 35-62;
https://link.springer.com/chapter/10.1007%2F82_2019_148
View PDF
Washburn N, Schwab I, Ortiz D, Bhatnagar N, Lansing J, Medeiros A, Tyler S, Mekala D, Cochran E, Sarvaiya H, Garofalo K, Meccariello R, Meador J, Rutitzky L, Schultes B, Ling L, Avery W, Nimmerjahn F, Manning A, Kaundinya G and Bosques C.
Controlled tetra-Fc sialylation of IVIg results in a drug candidate with consistent enhanced anti-inflammatory activity.
PNAS 2015 112 (11) E1297-E1306; published ahead of print March 2, 2015, doi:10.1073/pnas.1422481112
PEGS - Boston, 2014. Embracing EmComplexity: Understanding IVIgto Rationally Design Novel Therapeutics
View PPT
M230 (CSL730), Recombinant Fc Multimer
Ortiz DF, Lansing JC, Rutitzky et al.
Elucidating the interplay between IgG-Fc valency and FcγR activation for the design of immune complex inhibitors.
Sci. Transl. Med.
8, 365ra158 (2016).
PEGS - Boston, 2015. Selective Modulation of Fc Receptors for Improved Therapy of Orphan Autoimmune Diseases: Lessons from IVIg
View PPT